Interim Data of Adcetris in Pediatric Patients Presented at ASCO Meeting

At a poster presentation at the American Society of Clinical Oncology meeting, Takeda Pharmaceutical Company Limited presented interim data from a Phase 1/2, open-label, multicenter study of the antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) in pediatric patients diagnosed with either CD30-positive relapsed or refractory Hodgkin lymphoma (HL) or relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).

Data was only presented from the Phase 1 part of the study. This phase evaluated the safety and maximum tolerated dose, and is the first clinical trial looking at Adcetris in pediatric patients. 

Said Kathleen Neville, M.D., M.S., Director, Experimental Therapeutics in Pediatric Cancer, Children’s Mercy Hospitals and Clinics, Kansas City, Mo.:

There is an unmet medical need for children diagnosed with relapsed or refractory HL or relapsed or refractory sALCL. We are encouraged by these early results and look forward to reporting data from the Phase 2 portion of the study when they are available.

The data were presented by Anna R.K. Franklin, M.D., Children's Cancer Hospital, MD Anderson Cancer Center, Houston, Texas. The study involved just 12 patients between 2 and 18 (median age: 14.5 years) diagnosed with relapsed or refractory HL (10 patients) or relapsed or refractory sALCL (two patients) with primary endpoints set at safety and pediatric maximum tolerated dose. 

Treatment-emergent adverse events (TEAEs) ≥ Grade 2 were nausea (eight patients), pyrexia (six patients), upper abdominal pain (four patients) and paresthesia (four patients).

Seven serious AEs (SAEs) of ≥ Grade 3 were reported in six patients (50 percent) at 1.8 mg/kg (which was determined to be the maximum tolerated dose), including pyrexia unrelated to treatment (one patient), hepatotoxicity and febrile neutropenia (one patient), anaphylactic reaction (one patient), supraventricular tachycardia unrelated to treatment (one patient), pain in extremity (one patient), and cardiac arrest resulting in death unrelated to treatment (one patient).

Secondary endpoints of overall response rate (ORR) and complete response rate (CR) were available for eight patients and were reported as 88 percent and 38 percent respectively.

Source: ASCO 2013

More Articles

More Articles

Lymphoma patients may have the option to participate in clinical trials, gaining access to an experimental treatment before it is widely available...

Since there are several subtypes of T cell lymphoma, there will necessarily be several non-specific T cell lymphoma...

In order to prevent developing any subtype of lymphoma, it would be helpful to know the causes of lymphoma. Unfortunately, in virtually every case...

After surviving lymphoma treatments, patients should be on the lookout for late effects. These are symptoms that arise well after treatment has...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

Since so many chemotherapy agents can affect a patient’s sex drive and fertility, thinking about these issues prior...

The short answer: both. Let's begin with a simple definition of radiation: Radiation is the energy emitted from an energy source. That energy...

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...